These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32344150)

  • 41. An updated patent review on ocular drug delivery systems with potential for commercial viability.
    Srivastava R; Pathak K
    Recent Pat Drug Deliv Formul; 2011 May; 5(2):146-62. PubMed ID: 21453249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular novel drug delivery: impacts of membranes and barriers.
    Barar J; Javadzadeh AR; Omidi Y
    Expert Opin Drug Deliv; 2008 May; 5(5):567-81. PubMed ID: 18491982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microdialysis assessment of drug delivery systems for vitreoretinal targets.
    Duvvuri S; Rittenhouse KD; Mitra AK
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2080-91. PubMed ID: 16271800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics.
    Grimaudo MA; Pescina S; Padula C; Santi P; Concheiro A; Alvarez-Lorenzo C; Nicoli S
    Expert Opin Drug Deliv; 2019 Apr; 16(4):397-413. PubMed ID: 30889977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical injuries of the eye: current concepts in pathophysiology and therapy.
    Wagoner MD
    Surv Ophthalmol; 1997; 41(4):275-313. PubMed ID: 9104767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenomes as therapeutic targets.
    Hamm CA; Costa FF
    Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in Molecular Understanding of Ocular Adnexal Disease.
    Verdijk RM
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000006
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent patents and advances in ophthalmic drug delivery.
    Janoria KG; Hariharan S; Dasari CR; Mitra AK
    Recent Pat Drug Deliv Formul; 2007; 1(2):161-70. PubMed ID: 19075883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contact lenses: promising devices for ocular drug delivery.
    Guzman-Aranguez A; Colligris B; Pintor J
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):189-99. PubMed ID: 23215541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetics and Common Ophthalmic Diseases.
    Li W; Liu J; Galvin JA
    Yale J Biol Med; 2016 Dec; 89(4):597-600. PubMed ID: 28018148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.
    Kang-Mieler JJ; Dosmar E; Liu W; Mieler WF
    Expert Opin Drug Deliv; 2017 May; 14(5):611-620. PubMed ID: 27551742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Epigenetics' implication in autism spectrum disorders: A review].
    Hamza M; Halayem S; Mrad R; Bourgou S; Charfi F; Belhadj A
    Encephale; 2017 Aug; 43(4):374-381. PubMed ID: 27692350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Sustainability of Anterior Segment Surgery].
    Miyata K
    Nippon Ganka Gakkai Zasshi; 2017 Mar; 121(3):249-91. PubMed ID: 30088408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
    Comstock TL; Sheppard JD
    Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic mechanisms and kidney diseases.
    Liakopoulos V; Georgianos PI; Eleftheriadis T; Sarafidis PA
    Curr Med Chem; 2011; 18(12):1733-9. PubMed ID: 21466478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.